Literature DB >> 31005356

Bronchiectasis: A Complex, Heterogeneous Disease.

Miguel Angel Martínez-García1, Casilda Olveira2, Luis Máiz3, Rosa M ª Girón4, Concepción Prados5, David de la Rosa6, Marina Blanco7, Alvar Agustí8.   

Abstract

Most areas of respiratory medicine continue to use an Oslerian approach, based on signs and symptoms, in which the disease is the center of all activity. However, this paradigm is changing. Now that lung diseases have been recognized as heterogeneous and complex, we are moving towards more personalized, precise, patient-oriented medicine. The aim of this review was to define the current state of the knowledge on bronchiectasis, or, more accurately, the bronchiectasis syndrome, as a multidimensional, systemic, heterogeneous, complex disease. We explore the advances that have already been made, and above all the many steps that are still to be taken. We also propose some tools which might facilitate the application of these concepts in clinical practice, and help us continue our journey towards a more holistic view of this disease.
Copyright © 2019 SEPAR. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Actividad biomarcador; BSI; Biomarker activity; Clinical phenotypes; Complejidad; Complexity; E-FACED; Endotipos; Endotypes; FACED; Fenotipos clínicos; Gravedad; Heterogeneidad; Heterogeneity; Impact; Impacto; Medicina personalizada; Personalized medicine: BSI; Severity

Mesh:

Year:  2019        PMID: 31005356     DOI: 10.1016/j.arbres.2019.02.024

Source DB:  PubMed          Journal:  Arch Bronconeumol (Engl Ed)        ISSN: 0300-2896            Impact factor:   4.872


  5 in total

1.  Effects of Pulmonary Rehabilitation on Systemic Inflammation and Exercise Capacity in Bronchiectasis: A Randomized Controlled Trial.

Authors:  Amanda Souza Araújo; Mara Rúbia Figueiredo; Isabella Lomonaco; Fernando Lundgren; Rafael Mesquita; Eanes Delgado Barros Pereira
Journal:  Lung       Date:  2022-05-11       Impact factor: 2.584

2.  Rationale and Clinical Use of Bronchodilators in Adults with Bronchiectasis.

Authors:  Miguel Ángel Martínez-García; Grace Oscullo; Alberto García-Ortega; Maria Gabriella Matera; Paola Rogliani; Mario Cazzola
Journal:  Drugs       Date:  2021-11-26       Impact factor: 9.546

3.  Network Pharmacology Analysis of the Therapeutic Mechanisms Underlying Beimu-Gualou Formula Activity against Bronchiectasis with In Silico Molecular Docking Validation.

Authors:  Xin Shen; Hong Li; Wen-Jun Zou; Jian-Ming Wu; Long Wang; Wei Wang; Hui Chen; Ling-Li Zhou; Yuan-Hui Hu; Xu-Hua Qin; Jing Yang
Journal:  Evid Based Complement Alternat Med       Date:  2021-01-05       Impact factor: 2.629

4.  Systemic Inflammatory Biomarkers Define Specific Clusters in Patients with Bronchiectasis: A Large-Cohort Study.

Authors:  Xuejie Wang; Carmen Villa; Yadira Dobarganes; Casilda Olveira; Rosa Girón; Marta García-Clemente; Luis Máiz; Oriol Sibila; Rafael Golpe; Rosario Menéndez; Juan Rodríguez-López; Concepción Prados; Miguel Angel Martinez-García; Juan Luis Rodriguez; David de la Rosa; Xavier Duran; Jordi Garcia-Ojalvo; Esther Barreiro
Journal:  Biomedicines       Date:  2022-01-21

5.  Prognostic performance of the FACED score and bronchiectasis severity index in bronchiectasis: a systematic review and meta-analysis.

Authors:  Min He; Min Zhu; Chengdi Wang; Zuohong Wu; Xiaofeng Xiong; Hongxia Wu; Deyun Cheng; Yulin Ji
Journal:  Biosci Rep       Date:  2020-10-30       Impact factor: 3.840

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.